Company intelligence / Profile preview

Cell X Technologies

Cleveland, Ohio, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Celligent platform enables automated, reproducible, GMP-compliant manufacturing of cell therapies by integrating robotics, imaging, and artificial intelligence. Used for autologous and allogeneic cell therapy, tissue engineering, and artificial organ manufacturing. Recent collaborations with Aspen Neuroscience support scalable iPSC-based regenerative medicine workflows.

Modalities: Cell therapyInduced pluripotent stem cell derived therapyStem cell therapyTissue engineering platformsArtificial organ platform
Industry: Non-Drug Biotech

Partnerships

Aspen Neuroscience (collaboration for iPSC cell processing and manufacturing automation for autologous therapy)

Beyond the preview

Go deeper on Cell X Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell X Technologies.

Explore the full profile